Houston-area NASA astronauts Robert Behnken and Douglas Hurley will make a historic flight. Photo courtesy of NASA

Update: The launch was scrubbed a few minutes before launch due to undesirable weather conditions. The new launch date is Saturday, May 30, at around 2:30 CST. The original story is below.

Two Houston-area NASA astronauts are set to make history. Robert Behnken and Douglas Hurley will blast off on Elon Musk's SpaceX's Crew Dragon spacecraft, a Falcon 9 rocket, at 3:33 pm (CST) Wednesday, May 27, from the Kennedy Space Center in Cape Canaveral, Florida.

The flight is currently scheduled as a 60-percent "go" for launch as of May 27, with only inclement weather or a technical issue holding up the takeoff. Due to COVID-19 and subsequent social distancing issue, the launch will see only a small crowd at the Cape Canaveral takeoff.

The mission will carry the duo to the International Space Station and is considered a new era of human spaceflight, as American astronauts will once again launch on an American rocket from American soil to low-Earth orbit for the first time since the conclusion of the Space Shuttle Program in 2011, according to NASA.

NASA's SpaceX Demo-2 mission is the first launch with astronauts of the SpaceX Crew Dragon spacecraft and Falcon 9 rocket to the International Space Station as part of the agency's Commercial Crew Program. It's the final flight test for SpaceX; the mission will validate the company's crew transportation system, including the launch pad, rocket, spacecraft, and operational capabilities.

This also will be the first time NASA astronauts will test the spacecraft systems in orbit — Behnken and Hurley will don new, specially designed spacesuits and use touchscreen computers systems. The pairing of NASA — a governmental agency — and SpaceX, a commercial space flight operation, means NASA could save tens of millions in flight costs and instead focus on its Artemis mission to the moon, for example.

"The ultimate goal for us as astronauts and test pilots is just to go up there and prove out the mission and to bring the vehicle home safely," Hurley told CultureMap news partner, ABC13.

Proud Houstonians can watch NASA's coverage, which began at 11:15 am Wednesday, May 27, and will run through the Crew Dragon's docking at the International Space Station on Thursday, May 28. Expect a hatch opening and welcoming ceremony.

As part of the pre-launch ceremonies, at 12:07 pm, Burleson, Texas native Kelly Clarkson sang the National Anthem.

A special called Space Launch Live: America Returns to Space airs at 1 pm on the Discovery and Science Channel and will feature special celebrity guests including singer Katy Perry, Adam Savage, former NASA engineer and YouTube star Mark Robert, and astronaut Chris Cassidy from the International Space Station.

Meanwhile, launch and prelaunch activities on YouTube, Twitter, Facebook, and even Linkedin. For those watching at home and looking for a festive theme, Space Center Houston created an at-home viewing guide, including a playlist, outfits, and space food.

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Nominations are now open for the 2025 Houston Innovation Awards

Calling All Innovators

Calling all Houston innovators: The Houston Innovation Awards return this fall to celebrate the best and brightest in the Houston innovation ecosystem right now.

Presented by InnovationMap, the fifth annual Houston Innovation Awards will take place November 5 at TMC Helix Park.

The awards program will honor the top startups and innovators in Houston across 10 categories, and we're asking you to nominate the most deserving Houston innovators and innovative companies today.

This year's categories are:

  • Minority-founded Business, honoring an innovative startup founded or co-founded by BIPOC or LGBTQ+ representation.
  • Female-founded Business, honoring an innovative startup founded or co-founded by a woman.
  • Energy Transition Business, honoring an innovative startup providing a solution within renewables, climatetech, clean energy, alternative materials, circular economy, and beyond.
  • Health Tech Business, honoring an innovative startup within the health and medical technology sectors.
  • Deep Tech Business, honoring an innovative startup providing technology solutions based on substantial scientific or engineering challenges, including those in the AI, robotics, and space sectors.
  • Startup of the Year (People's Choice), honoring a startup celebrating a recent milestone or success. The winner will be selected by the community via an interactive voting experience.
  • Scaleup of the Year, honoring an innovative later-stage startup that's recently reached a significant milestone in company growth.
  • Incubator/Accelerator of the Year, honoring a local incubator or accelerator that is championing and fueling the growth of Houston startups.
  • Mentor of the Year, honoring an individual who dedicates their time and expertise to guide and support budding entrepreneurs.
  • Trailblazer, honoring an innovator who's made a lasting impact on the Houston innovation community.

Nominations may be made on behalf of yourself, your organization, and other leaders in the local innovation scene. The nomination period closes on August 31, so don't delay — nominate today at this link, or fill out the embedded form below.

Our panel of esteemed judges will review the nominations, and determine the finalists and winners. Finalists will be unveiled on September 30, and the 2025 Houston Innovation Awards winners will be announced live at our event on November 5.

Tickets will go on sale this fall. Stay tuned for that announcement, as well as more fanfare leading up to the 2025 Houston Innovation Awards.

Nominate now:

Interested in Innovation Awards sponsorship opportunities? Please contact sales@innovationmap.com.

MD Anderson launches $10M collaboration to advance personalized cancer treatment tech

fighting cancer

The University of Texas MD Anderson Cancer Center and Japan’s TOPPAN Holdings Inc. have announced a strategic collaboration to co-develop TOPPAN Holdings’ 3D cell culture, or organoid, technology known as invivoid.

The technology will be used as a tool for personalized cancer treatments and drug screening efforts, according to a release from MD Anderson. TOPPAN has committed $10 million over five years to advance the joint research activities.

“The strategic alliance with MD Anderson paves a promising path toward personalized cancer medicine," Hiroshi Asada, head of the Business Innovation Center at TOPPAN Holdings, said in a news release.

Invivoid is capable of establishing organoid models directly from patient biopsies or other tissues in a way that is faster and more efficient. Researchers may be able to test a variety of potential treatments in the laboratory to understand which approach may work best for the patient, if validated clinically.

“Organoids allow us to model the three-dimensional complexity of human cancers in the lab, thus allowing us to engineer a powerful translational engine—one that could not only predict how patients will respond to therapy before treatment begins but also could help to reimagine how we discover and validate next-generation therapies," Dr. Donna Hansel, division head of pathology and laboratory medicine at MD Anderson, added in the news release. “Through this collaboration, we hope to make meaningful progress in modeling cancer biology for therapeutic innovation.”

The collaboration will build upon preclinical research previously conducted by MD Anderson and TOPPAN. The organizations will work collaboratively to obtain College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) certifications for the technology, which demonstrate a commitment to high-quality patient care. Once the certifications are obtained, they plan to conduct observational clinical studies and then prospective clinical studies.

“We believe our proprietary invivoid 3D cell culture technology, by enabling the rapid establishment of organoid models directly from patient biopsies, has strong potential to help identify more effective treatment options and reduce the likelihood of unnecessary therapies,” Asada added in the release. “Through collaboration on CAP/CLIA certification and clinical validation, we aim to bring this innovation closer to real-world patient care and contribute meaningfully to the advancement of cancer medicine."